NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats.

@article{Wilson2019NP03AM,
  title={NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats.},
  author={Edward N. Wilson and Sonia Do Carmo and Lindsay A. Welikovitch and H{\'e}l{\`e}ne Hall and Lisi Flores Aguilar and Morgan K Foret and Maria Florencia Iulita and Dan Tong Jia and Adam R. Marks and Simon Allard and Joshua T. Emmerson and Adriana Ducatenzeiler and A. Claudio Cuello},
  journal={Journal of Alzheimer's disease : JAD},
  year={2019}
}
Epidemiological, preclinical, and clinical studies have suggested a role for microdose lithium in reducing Alzheimer's disease (AD) risk by modulating key mechanisms associated with AD pathology. The novel microdose lithium formulation, NP03, has disease-modifying effects in the McGill-R-Thy1-APP transgenic rat model of AD-like amyloidosis at pre-plaque stages, before frank amyloid-β (Aβ) plaque deposition, during which Aβ is primarily intraneuronal. Here, we are interested in determining… 
Forsythoside B attenuates memory impairment and neuroinflammation via inhibition on NF-κB signaling in Alzheimer’s disease
TLDR
F TS•B effectively counteracted cognitive decline by regulating neuroinflammation via NF-κB signaling in APP/PS1 mice, providing preliminary experimental evidence that FTS•B is a promising therapeutic agent in AD treatment.
Interplay of curcumin and its liver metabolism on the level of Aβ in the brain of APPswe/PS1dE9 mice before AD onset.
TLDR
The findings show that curcumin administration before Aβ deposition shows promise for preventing AD, and further thatCurcumin may play an important role in the clearance of Aβ42 from the brain to the peripheral circulation.
Microdose Lithium Treatment Reduced Inflammatory Factors and Neurodegeneration in Organotypic Hippocampal Culture of Old SAMP-8 Mice
TLDR
It is concluded that very low doses of Li 2 CO 3 can play an important role in neuroprotection as it can reduce neuronal loss and neuroinflammation in older individuals.
Lithium ions display weak interaction with amyloid-beta (Aβ) peptides and have minor effects on their aggregation
TLDR
It is shown that Li+ ions display weak and non-specific interactions with Aβ peptides, and have minor effects on Aβ aggregation, indicating that possible beneficial effects of Li on AD pathology are not likely caused by direct interactions between A β peptides andLi+ ions.
Neuronal–Glial Interaction in a Triple-Transgenic Mouse Model of Alzheimer’s Disease: Gene Ontology and Lithium Pathways
TLDR
It is concluded that neuronal-glial interactions are implicated in the neuroprotective response mediated by lithium in the hippocampus of AD-transgenic mice, which may be relevant for the survival of nerve cells amidst AD pathology.
Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?
TLDR
Evidence that low-dose lithium can reduce the SASP of human iPSCs-derived astrocytes following acute treatment is presented, suggesting that microdose lithium could protect cells from senescence and development of aging-related conditions.
The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer’s Disease
TLDR
How therapeutic strategies that attenuate pathological tau species in combination with treatments that improve mitochondrial biology could be a potential therapeutic avenue to mitigate disease progression in AD and other tauopathies is discussed.
Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s Disease, Lithium, and Autophagy
TLDR
Lithium’s neurobiological properties as evidenced by its neurotrophic and neuroprotective properties, as well as translational studies in cells in culture, in animal models of Alzheimer's disease and in patients, are reviewed, discussing the rationale for the drug’'s use in the treatment of AD.
...
...

References

SHOWING 1-10 OF 85 REFERENCES
Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis.
TLDR
Results suggest that NP03 may function to slow the AD-like pathology in part by modifying oxidative/nitrosative damage and neuroinflammation, raising the possibility that low doses of microencapsulated lithium might be of therapeutic-preventive value during very early or preclinical AD.
BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology
TLDR
A novel microdose formulation of lithium, coded NP03, is evaluated in a well-characterized rat model of progressive AD-like amyloid pathology and it is found that NP03 rescued key initiating components of AD pathology, including inactivating GSK-3β, reducing BACE1 expression and activity, and reducing amyloids levels.
Age-dependent inverse correlations in CSF and plasma amyloid-β(1–42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice
TLDR
The data suggests that there is an inverse correlations between the plasma and CSF Aβ(1–42) levels until plaques form in transgenic mice’s brains and that the plasma Aβ concentration possesses the diagnostic potential as a biomarker for diagnosis of early AD stages.
Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice.
TLDR
The data suggest that cholinergic denervation may trigger Aβ deposition and synergistically contribute to cognitive impairment in AD patients and there was a synergistic effect between cholinergy denervation and the presence of APP/PS1 transgenes.
A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.
TLDR
A new transgenic rat line, coded McGill-R-Thy1-APP, developed to express the human amyloid-beta precursor protein (AbetaPP) carrying both the Swedish and Indiana mutations under the control of the murine Thy1.2 promoter is described.
Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1‐Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease
TLDR
Blockade of CRTC1‐dependent gene expression in the early, preplaque phase of AD‐like pathology provides a molecular basis for the cognitive deficits that figure so prominently in early AD.
Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study
TLDR
The results demonstrate that the intraneuronal development of AD-like amyloid pathology includes a mixture of molecular species (Aβ, APP and CTFs) of which a considerable component is Aβ; and that the early presence of these species within neurons has deleterious effects in the CNS, even before the development of full-blown AD- like pathology.
Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease.
TLDR
The efficacy of a microdose lithium treatment in preventing cognitive loss is suggested, reinforcing its therapeutic potential to treat AD using very low doses.
Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents
TLDR
Findings provide strong evidence that endogenously generated human Aß selectively disrupts the induction of long-term potentiation in a manner that enables potential therapeutic options to be assessed longitudinally at the pre-plaque stage of Alzheimer’s disease amyloidosis.
...
...